What's Happening?
Savara Inc. presented new biomarker data from its IMPALA-2 Phase 3 clinical trial at the American Thoracic Society International Conference. The trial evaluates molgramostim inhalation solution for treating autoimmune pulmonary alveolar proteinosis (aPAP).
The study involved 164 patients receiving either molgramostim or a placebo over 48 weeks. Results showed significant improvements in pulmonary gas transfer and reductions in disease severity biomarkers for those treated with molgramostim compared to the placebo group.
Why It's Important?
The findings from Savara's trial are significant for patients with aPAP, a rare lung disease with limited treatment options. The improvement in pulmonary function and reduction in disease biomarkers suggest that molgramostim could become a viable treatment, potentially improving quality of life for patients. This development also highlights the importance of continued research and innovation in rare diseases, which often lack sufficient therapeutic options.
